Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Otsuka Pharmaceutical Development & Commercialization, Inc.

4 clinical trials · 4 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Otsuka Pharmaceutical Development & Commercialization, Inc.

RECRUITINGPhase 1NCT06799520

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171...

The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The...

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 306 locations
Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
RECRUITINGPhase 3NCT07209761

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant...

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 53220 locations
Pulmonary Tuberculosis
RECRUITINGPhase 3NCT06971731

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)

The goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with...

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 12020 locations
Phenylketonuria
RECRUITINGPhase 2NCT06637514

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with...

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 101 location
Phenylketonuria (PKU)